Veracyte Inc (NASDAQ:VCYT) Sellers Rose Their Shorts By 3.35%

June 27, 2018 - By Maria Fierro

Veracyte, Inc. (NASDAQ:VCYT) Corporate Logo

Big Money Sentiment decreased to 1.04 in 2018 Q1. It has change of 0.19, from 2017Q4’s 1.23. The ratio dropped due to Veracyte, Inc. positioning: 4 sold and 24 reduced. 11 funds acquired holdings and 18 increased holdings. Investors holded 21.45 million in 2017Q4 but now own 20.91 million shares or 2.49% less.
Perkins Mngmt holds 19,380 shs. Fin Mngmt Professionals has invested 0% of its capital in Veracyte, Inc. (NASDAQ:VCYT). Broadfin Cap Limited Co accumulated 0.52% or 600,658 shs. New York State Common Retirement Fund, New York-based fund reported 25,200 shs. Citadel Advsrs Limited holds 0% in Veracyte, Inc. (NASDAQ:VCYT) or 11,178 shs. Cannell Cap holds 3.68% in Veracyte, Inc. (NASDAQ:VCYT) or 2.06 million shs. Tpg Grp (Sbs) Inc holds 0.3% or 3.55M shs. Germany-based Deutsche Retail Bank Ag has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Amer Intll Grp Inc Inc owns 15,140 shs. Sg Americas Limited Liability Corp owns 14,670 shs. Renaissance Ltd Limited Liability Company has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Eventide Asset Management Limited Co reported 2.13M shs or 0.56% of all its holdings. Schwab Charles Investment Management has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Goldman Sachs Grp Inc invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Ameritas Invest Partners holds 1,394 shs or 0% of its capital.

Veracyte, Inc. registered $276,513 net activity with 0 buys and 2 sales since June 12, 2018. Hall Christopher M sold $180,464 worth of Veracyte, Inc. (NASDAQ:VCYT) on Friday, June 15.

Veracyte Inc (NASDAQ:VCYT) had an increase of its short interest by 3.35%. It was published in June by FINRA the 836,700 short interest on VCYT. That’s 3.35% up from 809,600 shares. Previous VCYT’s position will need 6 days to restore. It has 137,100 average volume. Veracyte Inc float short is 4.01%.

The last price was $9.29.Since June 27, 2017 it’s 6.02% down thus downtrending. The stock underperformed the S&P 500 by 18.59%.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States.The company has $319.07 million market cap. The firm uses genomic technology to resolve diagnostic ambiguity.Currently it has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Another two news for Veracyte, Inc. (NASDAQ:VCYT) were briefly released by: Globenewswire.com on June 21, 2018 with title “New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business …”. The other Businesswire.com‘s article was titled “Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year” and released on June 25, 2018.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.